Last reviewed · How we verify

Postherpetic neuralgia — Treatment Landscape & Competitive Intelligence

Postherpetic neuralgia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Postherpetic neuralgia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Horizant GABAPENTIN ENACARBIL Azurity Anti-epileptic Agent Voltage-dependent calcium channel subunit alpha-2/delta-1 2011-01-01
Qutenza CAPSAICIN Averitas capsaicin Transient receptor potential cation channel subfamily V member 1 2009-01-01
Neurontin gabapentin Generic (originally Parke-Davis/Pfizer) Gabapentinoid (anticonvulsant/neuropathic pain agent) Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor 1993-12-30
Lignospan Forte Lidocaine Hydrochloride Fresenius Kabi local anesthetic, amide type neuronal membrane ionic channels 1948-01-01
gabapentine gabapentine Dominik Irnich Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor
Horizant Horizant University of Missouri-Columbia Voltage-dependent calcium channel subunit alpha-2/delta-1, Voltage-dependent calcium channel subunit alpha-2/delta-2
Lidocain Lidocain Bayer 5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lyrica Pregabalin Pfizer Inc. Anticonvulsant, analgesic alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)
xylocain xylocain Saint-Joseph University 5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lignocaine Lignocaine University of Malaya 5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 2 drugs in Postherpetic neuralgia
  2. Azurity · 1 drug in Postherpetic neuralgia
  3. Bayer · 1 drug in Postherpetic neuralgia
  4. Daiichi Sankyo · 1 drug in Postherpetic neuralgia
  5. Dominik Irnich · 1 drug in Postherpetic neuralgia
  6. Fresenius Kabi · 1 drug in Postherpetic neuralgia
  7. Generic (originally Parke-Davis/Pfizer) · 1 drug in Postherpetic neuralgia
  8. Saint-Joseph University · 1 drug in Postherpetic neuralgia
  9. University of Malaya · 1 drug in Postherpetic neuralgia
  10. Averitas · 1 drug in Postherpetic neuralgia
  11. University of Missouri-Columbia · 1 drug in Postherpetic neuralgia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Postherpetic neuralgia:

Cite this brief

Drug Landscape (2026). Postherpetic neuralgia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/postherpetic-neuralgia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing